-
公开(公告)号：US12084418B2
公开(公告)日：2024-09-10
申请号：US17556820
申请日：2021-12-20
IPC分类号： C07D209/36 , C07D209/08 , C07D333/54
CPC分类号： C07D209/36 , C07D209/08 , C07D333/54
摘要： The disclosure relates to novel compounds and methods of use of the compounds to maintain the Gαi2 protein in its inactive GDP-bound state. The disclosure describes the knockdown or inhibition of Gαi2 negatively regulated migration of breast and ovarian cancer cell lines. The novel compounds inhibit the migratory behavior of PC3, DU145 and E006AA prostate cancer cell lines. Specifically, the novel compounds block the activation of Gαi2 in oxytocin-stimulated prostate cancer PC3 cells and inhibits the migratory capability of DU145 cells overexpressing constitutively active form of Gαi2, under basal and EGF-stimulated conditions.
-
2.发明公开公开(公告)号：US20240166620A1
公开(公告)日：2024-05-23
申请号：US18368576
申请日：2023-09-15
发明人： Xiaolei HUANG , Bingbin YANG , Yaoyao LU , Yaolin XIA , Xiaoyu MA
IPC分类号： C07D333/54 , C07D333/56 , C09K11/06
CPC分类号： C07D333/54 , C07D333/56 , C09K11/06 , C09K2211/1011
摘要： A fluorescent material containing a thiophene sulfone-olefin structural unit and a preparation method thereof are provided. In the preparation method, the thiophene sulfone compounds, olefins, oxidants and additives are dissolved in the tetrahydrofuran solvent, and are subjected to a reaction under the catalytic action of the palladium catalyst, and the alkenylated thiophene sulfone products with obvious fluorescence emission characteristics of liquid and solid can be obtained. The preparation method expands the range of substrates well, featuring good regional selectivity, high yield, mild reaction conditions and simple operation.
-
公开(公告)号：US11780829B2
公开(公告)日：2023-10-10
申请号：US16744728
申请日：2020-01-16
发明人： Mark E. Thompson , Abegail Tadle , Karim El Roz , Peter Ivan Djurovich , Daniel Sylvinson Muthiah Ravinson , Jessica H. Golden , Stuart W. Sawyer
IPC分类号： H01L51/00 , C07D405/14 , C07D209/82 , C07D251/24 , C07D333/54 , C07D403/04 , C07D403/14 , C07D409/14 , C07F7/08 , H10K85/40 , H10K85/60
CPC分类号： C07D405/14 , C07D209/82 , C07D251/24 , C07D333/54 , C07D403/04 , C07D403/14 , C07D409/14 , C07F7/0812 , H10K85/40 , H10K85/622 , H10K85/6572 , H10K85/6574 , H10K85/6576
摘要： A compound of Formula X
wherein
ring A is absent, or present and selected from a 5-membered or 6-membered, carbocyclic or heterocyclic ring, which is optionally substituted; ring B is absent, or present and selected from a 5-membered or 6-membered, carbocyclic or heterocyclic ring, which is optionally substituted; and at least one of ring A or ring B is present, and the hash line represents ring A fused to ring N—W1—W3 and ring B fused to ring N—W4—W6;
W1, W2, W3, W4, W5, and W6 are independently selected from CR1 or N;
Z is selected from CRZ or N; and Y is selected from a group consisting of C(R2)2, B(R2)2, Al(R2)2, Si(R2)2, and Ge(R2)2.
An optoelectronic device selected from the group consisting of a photovoltaic device, a photodetector device, a photosensitive device, and an OLED, the optoelectronic device including an organic layer that comprises a compound of Formula X. A consumer product that includes the optoelectronic device.-
公开(公告)号：US11691957B2
公开(公告)日：2023-07-04
申请号：US16897189
申请日：2020-06-09
发明人： Yongsik Jung , Wataru Sotoyama , Hosuk Kang , Sungjun Kim , Joonghyuk Kim , Youngmok Son , Won-Joon Son , Yeonsook Chung
IPC分类号： C07D307/79 , C07D407/04 , C07D409/04 , C07D407/10 , C07D333/54 , C07D409/14 , C07D409/10 , C07D405/04 , C07D413/10 , C07D471/04 , C07F7/08 , H10K85/40 , H10K85/60 , H10K50/17 , H10K50/12 , C07D405/10 , C07D413/04 , C07D419/04 , C07D407/14 , C07D333/72 , H01L51/00 , H01L51/50 , C07D307/87 , H01L51/42
CPC分类号： C07D307/79 , C07D307/87 , C07D333/54 , C07D333/72 , C07D405/04 , C07D405/10 , C07D407/04 , C07D407/10 , C07D407/14 , C07D409/04 , C07D409/10 , C07D409/14 , C07D413/04 , C07D413/10 , C07D419/04 , C07D471/04 , C07F7/0816 , H01L51/0065 , H01L51/0068 , H01L51/0069 , H01L51/0072 , H01L51/0073 , H01L51/0074 , H01L51/0094 , H01L51/5024 , H01L51/5092 , H01L51/4273 , H01L51/5056 , H01L51/5072
摘要： Provided are a condensed cyclic compound represented by Formula 1 and an organic light-emitting device including the same:
wherein, in Formula 1, X1, A1, L11, a11, Ar11, Ar12, b11, R11, R12, c11, and c12 are the same as defined in the specification.-
公开(公告)号：US11673885B2
公开(公告)日：2023-06-13
申请号：US17241662
申请日：2021-04-27
IPC分类号： C07D411/06 , C07D213/50 , C07D317/46 , C07D319/16 , C07D327/06 , C07D339/08 , C07D401/06 , C07D405/06 , C07D409/06 , C07D263/56 , C07D311/58 , C07D317/54 , C07D319/18 , C07D231/56 , C07D333/54 , C07D235/06 , C07D407/06 , C07D413/06 , C07D307/80 , A61P25/00
CPC分类号： C07D411/06 , A61P25/00 , C07D213/50 , C07D231/56 , C07D235/06 , C07D263/56 , C07D307/80 , C07D311/58 , C07D317/46 , C07D317/54 , C07D319/16 , C07D319/18 , C07D327/06 , C07D333/54 , C07D339/08 , C07D401/06 , C07D405/06 , C07D407/06 , C07D409/06 , C07D413/06
摘要： The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
-
公开(公告)号：US20190177309A1
公开(公告)日：2019-06-13
申请号：US16274352
申请日：2019-02-13
IPC分类号： C07D409/14 , C07D333/54 , C07D247/02 , A61K31/496 , C07D401/12 , A61K9/14
CPC分类号： C07D409/14 , A61K9/14 , A61K31/496 , B01D9/02 , C07D247/02 , C07D333/54 , C07D401/12 , C07D409/12 , C07D487/10
摘要： The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.
-
公开(公告)号：US20180071304A1
公开(公告)日：2018-03-15
申请号：US15817470
申请日：2017-11-20
申请人： vTv Therapeutics LLC
发明人： Per Sauerberg , Pavel Pihera , Zdenek Polivka , Miroslav Havranek , Ingrid Pettersson , John Patrick Mogensen
IPC分类号： A61K31/5377 , A61K31/495 , A61K31/343 , A61K31/4025 , A61K31/381 , A61K31/445 , A61K31/195 , A61K31/4402 , A61K31/415 , A61K31/5375 , A61K31/192 , A61K31/40
CPC分类号： A61K31/5377 , A61K31/192 , A61K31/195 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/415 , A61K31/4402 , A61K31/445 , A61K31/495 , A61K31/5375 , C07C59/70 , C07C217/48 , C07C323/16 , C07C323/32 , C07C2601/02 , C07D211/46 , C07D213/30 , C07D213/36 , C07D231/12 , C07D265/30 , C07D295/096 , C07D295/112 , C07D307/79 , C07D307/81 , C07D333/16 , C07D333/20 , C07D333/54
摘要： Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same.
-
公开(公告)号：US20170260176A1
公开(公告)日：2017-09-14
申请号：US15356903
申请日：2016-11-21
申请人： Samumed, LLC
IPC分类号： C07D411/06 , C07D311/58 , C07D317/54 , C07D319/18 , C07D231/56 , C07D333/54 , C07D235/06 , C07D407/06 , C07D413/06 , C07D307/80 , C07D213/50 , C07D317/46 , C07D319/16 , C07D327/06 , C07D339/08 , C07D401/06 , C07D405/06 , C07D263/56 , C07D409/06
CPC分类号： C07D411/06 , C07D213/50 , C07D231/56 , C07D235/06 , C07D263/56 , C07D307/80 , C07D311/58 , C07D317/46 , C07D317/54 , C07D319/16 , C07D319/18 , C07D327/06 , C07D333/54 , C07D339/08 , C07D401/06 , C07D405/06 , C07D407/06 , C07D409/06 , C07D413/06
摘要： The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
-
公开(公告)号：US20170216303A1
公开(公告)日：2017-08-03
申请号：US15490205
申请日：2017-04-18
申请人： vTv Therapeutics LLC
发明人： Per Sauerberg , Pavel Pihera , Zdenek Polivka , Miroslav Havranek , Ingrid Pettersson , John Patrick Mogensen
IPC分类号： A61K31/5377 , A61K31/5375 , A61K31/415 , A61K31/4402 , A61K31/495 , A61K31/40 , A61K31/445 , A61K31/381 , A61K31/4025 , A61K31/343 , A61K31/192 , A61K31/195
CPC分类号： A61K31/5377 , A61K31/192 , A61K31/195 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/415 , A61K31/4402 , A61K31/445 , A61K31/495 , A61K31/5375 , C07C59/70 , C07C217/48 , C07C323/16 , C07C323/32 , C07C2601/02 , C07D211/46 , C07D213/30 , C07D213/36 , C07D231/12 , C07D265/30 , C07D295/096 , C07D295/112 , C07D307/79 , C07D307/81 , C07D333/16 , C07D333/20 , C07D333/54
摘要： Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same.
-
10.发明申请RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, ACID GENERATOR, PHOTOREACTIVE QUENCHER, AND COMPOUND 有权耐蚀组合物，耐热型图案的形成方法，酸发生器，光电检测器和化合物公开(公告)号：US20160280679A1
公开(公告)日：2016-09-29
申请号：US15077034
申请日：2016-03-22
发明人： Takashi NAGAMINE , Kotaro ENDO , Miki SHINOMIYA
IPC分类号： C07D333/54 , G03F7/20 , G03F7/32 , C07C309/06 , C07C309/19 , C07D327/04 , C07D285/16 , C07D493/08 , G03F7/038 , G03F7/004
CPC分类号： C07D333/54 , C07C53/21 , C07C61/135 , C07C65/10 , C07C307/02 , C07C309/06 , C07C309/12 , C07C309/17 , C07C309/19 , C07C311/04 , C07C2603/68 , C07C2603/74 , C07D285/16 , C07D327/04 , C07D493/08 , G03F7/0045 , G03F7/0046 , G03F7/0397
摘要： A resist composition which generates acid upon exposure and exhibits changed solubility in a developing solution under action of acid, and which includes a base component which exhibits changed solubility in a developing solution under action of acid and an acid-generator component including a compound (B0-1) represented by general formula (b0) shown below in which Ra1 represents an aromatic ring; Ra01 represents an alkyl group of 5 or more carbon atoms optionally having a substituent; Ra02 and Ra03 each independently represents an alkyl group of 1 to 10 carbon atoms optionally having a substituent; n1 represents an integer of 1 to 5; n2 represents an integer of 0 to 2;n3 represents an integer of 0 to 4; and X− represents a counteranion.
-
-
-
-
-
-
-
-
-
搜索结果
748 条记录 (耗时 0.043 秒)
